Janus Henderson Group PLC Buys 613,294 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Janus Henderson Group PLC lifted its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 259.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 849,410 shares of the company's stock after purchasing an additional 613,294 shares during the quarter. Janus Henderson Group PLC owned about 2.43% of Oruka Therapeutics worth $16,415,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after buying an additional 1,572,853 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Oruka Therapeutics by 374.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock worth $25,730,000 after acquiring an additional 1,047,245 shares during the last quarter. FMR LLC lifted its holdings in shares of Oruka Therapeutics by 17.7% in the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock worth $106,883,000 after acquiring an additional 830,000 shares during the last quarter. Braidwell LP boosted its stake in shares of Oruka Therapeutics by 122.5% during the 4th quarter. Braidwell LP now owns 1,147,676 shares of the company's stock worth $22,253,000 after purchasing an additional 631,950 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new position in shares of Oruka Therapeutics during the 4th quarter worth about $6,787,000. Institutional investors own 56.44% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ORKA. Wedbush reissued an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, Wolfe Research started coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price target for the company. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Oruka Therapeutics currently has a consensus rating of "Buy" and an average price target of $39.86.

Oruka Therapeutics Stock Performance

ORKA traded up $0.23 during trading on Wednesday, hitting $10.85. 28,002 shares of the stock were exchanged, compared to its average volume of 226,065. The firm has a 50 day simple moving average of $9.83 and a 200 day simple moving average of $14.54. The firm has a market cap of $406.05 million, a price-to-earnings ratio of -1.74 and a beta of 0.25. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. As a group, equities analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.